Clinical Review Of Transcatheter Hepatic Arterial Chemoembolization Combined With Microwave Ablation In Patients With Advanced Liver Cancer

Objective:To evaluate the clinical effect and application value of transcatheter hepatic arterial chemoembolization(TACE) combined with percutaneous microwave ablation therapy(PMCT) in patients with advanced liver cancer.Methods:Retrospective analysis of 83 patients with advanced liver cancer rece- ived TACE and TACE combined with PMCT in GuangXi Cancer Hospital from Dec- ember 2004 to September 2006 . 55 patients performed only in TACE were enrolled in control group. 28 patients were treated with TACE+PMCT as the therapy group . The patients were performed firstly in TACE and received 5-FU (750~1000mg) +EPI (40~60mg) or DDP (40~60mg)+the emulsion(10~30ml) constituted by MMC(10~14 mg )and LP (10~30ml) to chemoembolization feeding artery of liver cancer;And gelatin sponge particles were used to Strengthen the embolization necessarily. The HAPS were blocked up before cure tumor .CT inspection was performed after every post-Treatment 3~4 weeks.TACE or TACE+PMCT was selected to patients again accor- ding to the condition of fistula and tumor.The continuous three treatments was a period of treatment.Then followed up the therapeutic effect rates,reduced rates of AFP,side effects,the rates of recurrence and metastasis,survival time of the two groups . Results: The effect rates were 67.86% and 40.00% in the therapy group and the control group ,respectively(P<0.05);The average reduced rates of AFP was 76.00% and 47.92% in the therapy group and control group ,respectively(P<0.05);The med- ian survival time and 0.5-,1-,1.5-,2-year cumulative survival rate were 30 months,100% 93%,79%,61%and 24months,95%,84%,65%,36% in the therapy group and control group ,respectively(P<0.05);The 0.5-,1-,2-year cumulative recurrence and metastasis rate were 7.14%,14.29%,32.14% and 9.09%,34.55%,65.45% in the therapy group and control group ,respectively(P<0.05);The side effects of two groups were similar and the serious complications were not found;8 HAPS in the control group were blocked up repeatedly with TACE , 3 of them were recanalized yet. 5 HAPS in the therapy group were completely blocked, none of them was recanalized again.Conclusions:TACE combined with PMCT could safely and effectively treat the Patients with anvanced liver cancer,and extend life span, reduce recurrence rate and not increase side effects.